Evidence to date: talazoparib in the treatment of breast cancer
Pedro Exman, Romualdo Barroso-Sousa, Sara M TolaneyBreast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAAbstract: Approximately 5–10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-07-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/evidence-to-date-talazoparib-in-the-treatment-of-breast-cancer-peer-reviewed-article-OTT |